ScholarIQanswers from OpenAlex

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

PaperCitations, authors & open-access status

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer have?

ScholarIQcitation count

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer has 307 citations in the OpenAlex counts ScholarIQ stores.

When was Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer published?

ScholarIQyear

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer has 2016 year in the ScholarIQ index.

What is the open-access status of Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer?

ScholarIQoa status

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer has gold oa status in the ScholarIQ index.

What is the DOI of Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer?

ScholarIQdoi

The DOI for Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer is on the source record.

What is the PMID of Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer?

ScholarIQpmid

The PMID for Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer is on the source record.

What is the OpenAlex record for Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer?

ScholarIQopenalex

The OpenAlex for Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial